Bausch & Lomb Incorporated

78 total trials 34 currently recruiting 40 completed

Trial Pipeline

RECRUITING Phase 2

Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension

NCT07168902

RECRUITING Phase 2

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

NCT07128628

RECRUITING

IC-8 Apthera IOL New Enrollment Post Approval Study

NCT06060041

ACTIVE NOT RECRUITING Phase 1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers

NCT06978244

ACTIVE NOT RECRUITING NA

Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction

NCT06333015

ACTIVE NOT RECRUITING Phase 4

A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.

NCT06565650

ACTIVE NOT RECRUITING NA

Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism

NCT05264623

COMPLETED Phase 4

A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear

NCT07054606

COMPLETED NA

Orientation Characteristics of Daily Disposable Toric Contact Lenses

NCT06069609

COMPLETED Phase 3

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

NCT05815758

COMPLETED Phase 3

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

NCT05591755

COMPLETED NA

Insertion Clinical Study to Evaluate the Orientation Characteristics of Multiple Kalifilcon A Daily Disposable Toric LD213001 Contact Lenses

NCT05129124

COMPLETED Phase 3

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

NCT04140227

COMPLETED NA

Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to Dailies Total 1, Precision 1 and Biotrue ONEday Lenses

NCT04555031

COMPLETED Phase 1

Safety and IOP-Lowering Effects of WB007

NCT04149899

COMPLETED NA

A Safety and Effectiveness Study of a New Preservative Free Rewetting Drop

NCT04175340

COMPLETED NA

Product Performance of a New Silicone Hydrogel Contact Lens

NCT04901897

COMPLETED NA

A Study to Evaluate the Safety and Efficacy of Kalifilcon A Daily Disposable Contact Lens

NCT04158466

COMPLETED Phase 1

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

NCT03896633

COMPLETED NA

Clinical Study of Approved Contact Lenses

NCT03351101

COMPLETED Phase 3

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749930

COMPLETED Phase 3

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT01591161

COMPLETED NA

Evaluation of Ocular Comfort With ISTA Tears vs Systane

NCT01650584

COMPLETED NA

A Study to Evaluate the Product Feasibility of a New Silicone Hydrogel Contact Lens

NCT01412983

COMPLETED NA

A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens

NCT01416142

COMPLETED NA

Safety and Efficacy of a Contact Lens for Daily Disposable Use

NCT01365039

COMPLETED NA

Evaluation of Two Daily Disposable Contact Lenses.

NCT01300065

COMPLETED NA

A Study to Evaluate a New Silicone Hydrogel Contact Lens

NCT01309893

COMPLETED NA

Evaluation of a New Silicone Hydrogel Contact Lens

NCT01309880

COMPLETED NA

A Study to Evaluate the Performance of Two Designs of Soft Toric Lenses

NCT01309867

COMPLETED Phase 2

Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis

NCT01277341

COMPLETED Phase 3

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01230125

COMPLETED Phase 2

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge

NCT01107405

COMPLETED Phase 3

Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

NCT01060072

COMPLETED Phase 3

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.

NCT00770133

COMPLETED Phase 2

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

NCT00972777

COMPLETED Phase 3

Study of T-PRED(TM) Compared to Pred Forte(R) II

NCT00854061

COMPLETED Phase 3

Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery

NCT00699153

COMPLETED Phase 2

Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease

NCT00667004

COMPLETED NA

Safety and Efficacy of a Bausch & Lomb Multipurpose Solution When Compared to Ciba Vision Aquify Multipurpose Solution

NCT00636363

COMPLETED Phase 2

Efficacy and Safety of Bromfenac Ophthalmic Solution

NCT00585975

COMPLETED Phase 2

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

NCT00441883

COMPLETED Phase 2

Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis

NCT00424398

COMPLETED Phase 4

Pediatric Zylet Safety and Efficacy Study

NCT00420628

COMPLETED NA

A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)

NCT00347594

COMPLETED NA

A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia

NCT00348205

COMPLETED Phase 3

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

NCT00198510

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 40
Phase 3 11
Phase 4 3

What the Pipeline for Bausch & Lomb Incorporated Shows

According to the ClinicalTrials.gov registry, Bausch & Lomb Incorporated is linked to 78 US clinical trials across every stage of research activity. Of those, 34 studies are currently recruiting — about 44% of the sponsor's indexed portfolio — and 40 are already marked complete, representing roughly 51% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Bausch & Lomb Incorporated reports 14 late-stage studies (Phase 3 and Phase 4 combined) and 43 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Bausch & Lomb Incorporated is Myopia with 9 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial